PAVmed (NASDAQ:PAVM) posted its quarterly earnings results on Sunday. The company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.06), MarketWatch Earnings reports.
Shares of NASDAQ PAVM traded down $0.86 during trading on Tuesday, hitting $4.69. 330,471 shares of the company were exchanged, compared to its average volume of 4,408,917. The firm has a market capitalization of $337.23 million, a PE ratio of -5.46 and a beta of 0.13. The company has a fifty day moving average price of $2.59 and a 200-day moving average price of $2.08. PAVmed has a 12-month low of $1.30 and a 12-month high of $5.63.
PAVM has been the topic of several recent analyst reports. Ascendiant Capital Markets initiated coverage on shares of PAVmed in a research report on Thursday, November 5th. They set a “buy” rating and a $5.00 price objective on the stock. Lake Street Capital boosted their price objective on shares of PAVmed from $5.00 to $9.00 and gave the company a “buy” rating in a research report on Monday.
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
Recommended Story: What are momentum indicators and what do they show?
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.